Literatur
-
1
Barnard J P, Friedlander A M.
Vaccination against Anthrax with attenuated recombinant
strains of Bacillus anthracis that produce protective antigen.
Infect
Immun.
1999;
67
562-567
-
2 Bortolussi R, Kennedy W. Anthrax. London: Mosby In:
Armstrong D, Cohen J, editors. Infectious diseases. 1st
ed 1999: 8.15.7-9
-
3
Christopher G W, Cieslak T J, Pavlin J A, Eitzen E M.
Biological warfare: a historic
perspective.
JAMA.
1997;
278
412-417
-
4
Davies J C.
A major epidemic of anthrax in Zimbabwe.
Cent Afr J
Med
(Zimbabwe).
1982;
28
291-298
-
5
Demicheli V, Rivetti D, Decks J J, Jefferson T, Pratt M.
The effectiveness and safety of vaccines against human
anthrax: a systematic
review.
Vaccine.
1998;
16
880-884
-
6
Dixon T C, Meselson M, Guillemin J, Hanna P C.
Anthrax.
N Engl J
Med.
1999;
341
815-826
-
7 Eitzen E. Anthrax. Frederick, Maryland: US Army Medical
Research Institute of Infectious Diseases In: Eitzen E, Pavlin
C, editors. Medical Management of Biological Casualties Handbook 2nd
ed 1996: 16-22
-
8
Fellows P F, Linscott M K, Ivins B E. et al .
Efficacy of a human anthrax vaccine in guinea pigs, rabbits,
and rhesus macaques against challenges by Bacillus anthracis isolates of
diverse geographical
origin.
Vaccine.
2001;
19
3241-3247
-
9
Friedlander A M, Welkos S L, Pitt M L. et al .
Postexposure prophylaxis against experimental inhalation
anthrax.
J Infec
Dis.
1993;
167
1239-1243
-
10 Friedlander A M. Anthrax. Washington: TMM
Publications In: Sidell FR, Takafuji ET, Franz DR, editors.
Medical aspects of chemical and biological warfare. 1st
ed 1997: 467-478
-
11
Inglesby T V, Henderson D A, Bartlett J G. et al .
Anthrax as a biological
weapon.
JAMA.
1999;
281
1735-1745
-
12
Ivins B E, Pitt M L, Fellows P F. et al .
Comparative efficacy of experimental anthrax vaccine
canidates against inhalational anthrax in rhesus
macaques.
Vaccine.
1998;
16
1141-1148
-
13
Kim H L, Jun W B, Lee S H, Roo M H.
CT and MR findings of anthrax menigoencephalitis: report of
two cases and review of the literature.
Am J
Neuroradiol.
2001;
22
1303-1305
-
14
Leppla S H.
A dominant-negative therapy for anthrax.
Nature
Med.
2001;
7
659-660
-
15
Little S F, Ivins B E, Fellows P F, Friedlander A M.
Passive protection by polyclonal antibodies against Bacillus
anthracis infection in guinea pigs.
Infect
Immun.
1997;
65
5171-5175
-
16
Little S F, Ivins B E.
Molecular pathogenesis of Bacillus anthracis
infection.
Microbes
Infect.
1999;
1
131-139
-
17
Morgan M F.
Anthrax - an old disease returns as a bioterrorism
weapon.
New Jersey
Med.
2000;
97
35-41
-
18
Morris K.
US anthrax-vaccine producer saved for
now.
Lancet.
1998;
351
657
-
19
N.N. - Centers for Disease Control and
Prevention .
Update: adverse effects associated with anthrax prophylaxis
among postal employees - New Jersey, New York City, and the District of
Columbia Metropolitan
Area.
MMWR.
2001;
50
1051-1054
-
20
N.N. - Centers for Disease Control and
Prevention .
Investigation of bioterrorism-related anthrax- Connecticut,
2001.
MMWR.
2001;
50
1077-1079
-
21
N.N. - Centers for Disease Control and
Prevention .
Additional options for preventive treatment for persons
exposed to inhalational
anthrax.
MMWR.
2001;
50
1142-1151
-
22
N.N. - Centers for Disease Control and
Prevention .
Evaluation of postexposure antibiotic prophylaxis to prevent
anthrax.
MMWR.
2002;
51
59
-
23
Olsnes S, Wesche J.
Fighting anthrax with a mutant
toxin.
Science.
2001;
292
647-648
-
24
Pomerantsev A P, Staritsin N A, Mockov Y V, Marinin L I.
Expression of cerolysine AB genes in Bacillus anthracis
vaccine strain ensures protection against experimental hemolytic anthrax
infection.
Vaccine.
1997;
15
1846-1850
-
25
Price B M, Liner A L, Park S, Leppla S H, Mateczum A, Galloway D R.
Protection against anthrax lethal toxin challenge by genetic
immunization with a plasmid encoding the lethal factor
protein.
Infect
Immun.
2001;
69
4509-4515
-
26 Schnitzler N. Meldepflichtige Krankheiten. Stuttgart, Berlin,
Köln: Verlag W. Kohlhammer GmbH In: Bales S, Baumann HG,
editors. Infektionsschutzgesetz. 1st
ed 2001: 41-58
-
27
Sellmann B R, Mourez M, Collier R J.
Dominant-negative mutants of a toxin subunit: an approach to
therapy of
anthrax.
Science.
2001;
292
695-697
-
28
Shin S, Kim Y -B, Hur G -H.
Involvement of phosphlipase A2 activation in anthrax lethal
toxin-induced cytotoxicity.
Cell Biol
Toxicol.
1999;
15
19-29
-
29
Shin S, Hur G -H, Kim Y -B. et al .
Intracellular calcium antagonist protects cultured peritoneal
macrophages against anthrax lethal toxin-induced cytotoxicity.
Cell
Biol
Toxicol.
2000;
16
137-144
-
30
Shlyakhov E N, Rubinstein E, Novikov I.
Anthrax post-vaccinal cell-mediated immunity in humans:
kinetic
pattern.
Vaccine.
1997;
15
631-636
-
31
Shlyakhov E N, Rubinstein E.
Human live anthrax vaccine in the former
USSR.
Vaccine.
1994;
12
727-730
-
32
Sirard J C, Guidi-Rontani C, Fouet A, Mock M.
Characterization of a plasmid region involved in Bacillus
anthracis toxin production and pathogenesis.
Int J Med
Microbiol.
2000;
290
313-316
-
33 Theisohn M, Biederbick W, Rump A FE. Therapeutisches
Arzneimittelmonitoring. Zülpich: Biermann Verlag
GmbH In: Hummerich W, Keller R, Schrappe M editors. Klinischer
Leitfaden durch das Labor - Innere Medizin. 2nd
ed 1997: 426-427
-
34
Turnbull P CB, Broster M G, Carman J A, Manchee R J, Melling J.
Development of antibodies to protective antigen and lethal
factor components of anthrax toxin in humans and guinea pigs and their
relevance to protective immunity.
Infection
Immunity.
1986;
52
356-363
-
35
Turnbull P CB, Leppla S H, Broster M G, Quinn C P, Melling J.
Antibodies to anthrax toxin in humans and guinea pigs and
their relevance to protective immunity.
Med Microbiol
Immunol.
1988;
177
292-303
-
36 Turnbull P CB. Bacillus. Galveston: Univ Texas Medical
Branch In: Baron S, editor. Medical microbiology. 4th
ed 1996: 233-245
Korrespondenz
Dr. med. Walter Biederbick
Bundesministerium der Verteidigung, InSan I 1
Postfach 1328
53003 Bonn
Telefon: 0228/126247
Fax: 0228/127546
eMail: walterbiederbick@bmvg.bund400.de
